Ichnos Glenmark Innovation's ISB 2001 secures US FDA Fast Track designation for multiple myeloma
Based on the source material and analysis, here's a draft news brief:
Ichnos Glenmark Innovation Receives FDA Fast Track Designation for ISB 2001 in Multiple Myeloma
Ichnos Glenmark Innovation (IGI) announced today that the US FDA has granted Fast Track designation for ISB 2001, an investigational trispecific antibody targeting relapsed or refractory multiple myeloma (RRMM) in adult patients who have received at least three prior lines of therapy.
Multiple Myeloma: A Challenging Landscape
Multiple myeloma is a hematologic cancer characterized by the uncontrolled proliferation of plasma cells in the bone marrow. Nearly all patients with relapsed or refractory multiple myeloma ultimately experience disease progression, with limited treatment options once approved therapies are exhausted.
Innovative Therapeutic Approach
ISB 2001 is a first-in-class trispecific T-cell engager that simultaneously targets:
- BCMA and CD38 on myeloma cells
- CD3 on T cells
Developed using IGI's proprietary BEAT® protein platform, the antibody is engineered to enhance tumor targeting while potentially reducing off-tumor toxicity compared to first-generation bispecific antibodies.
Clinical Development Status
The drug is currently being evaluated in a Phase 1 dose-expansion study (NCT05862012) across nine sites in the United States and Australia. Initial clinical data presented at the American Society of Hematology Annual Meeting demonstrated a high overall response rate with durable responses and a favorable safety profile.
Regulatory Context
The FDA's Fast Track designation is designed to expedite the development and review of drugs treating serious conditions with unmet medical needs. ISB 2001 was previously granted Orphan Drug Designation in July 2023, further supporting its potential clinical significance.
Complete results from the dose-escalation portion of the study will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2025.
Spot something wrong? Report an issue with this article
Summary
Based on the source material and analysis, here's a draft news brief: # Ichnos Glenmark Innovation Receives FDA Fast Track Designation for ISB 2001 in Multiple...